BIO Bio-rad Laboratories (BIO) Insider Trading, Ownership & Congress Trades
Medical Devices · Laboratory analytical instruments · CIK 0000012208
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
177
13F, latest reported quarter
Conversions, 180 days
1
Codes C/M, not in net · $0 priced
What the filings say about BIO
Insiders, 180 days
-$135.6K net sold
1 seller · 0% of sales under a 10b5-1 plan
Bio-rad Laboratories insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, BIO-RAD LABORATORIES, INC. insiders sold a net $135.6K of stock across 41 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-27.
Insider
Filed
Shares
Value
Since filing
Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 159.0% of the 346 shares held after it.
- No other insider sold within 30 days.
- 177 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: EVP, President, CDG ENGELHARDT EVA ANETTE sold about $135.6K of BIO on May 11, 2026; 177 funds added in the latest 13F quarter.Context
- 1 earlier Form 4 trade (code P or S) here by this insider (1 sale), the last on Sep 4, 2024.
- The trade is 137.3% of the 509 shares held after it.
- No other insider sold within 30 days.
- 177 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: EVP, President, LSG BARRY JAMES sold about $214.3K of BIO on Nov 6, 2025; 177 funds added in the latest 13F quarter.Context
- 6 earlier Form 4 trades (code P or S) here by this insider (6 sales), the last on Jun 13, 2024.
- The trade is 36.7% of the 8,171 shares held after it.
- No other insider sold within 30 days.
- 177 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: EVP, GBL Commercial Operations Crowley Michael sold about $741.2K of BIO on Mar 14, 2025; 177 funds added in the latest 13F quarter.Context
- 3 earlier Form 4 trades (code P or S) here by this insider (3 sales), the last on Sep 1, 2021.
- The trade is 39.7% of the 7,559 shares held after it.
- 1 other insider sold within 30 days.
- 177 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: EVP, Chief Operating Officer Last Andrew J. sold about $989.8K of BIO on Sep 6, 2024; 1 other insider sold within 30 days and 177 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 425.1% of the 146 shares held after it.
- 1 other insider sold within 30 days.
- 177 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: EVP, President, LSG BARRY JAMES sold about $205.9K of BIO on Sep 4, 2024; 1 other insider sold within 30 days and 177 funds added in the latest 13F quarter.41 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net -$135.6K over 180 days
more than 52% of Medical Devices
Congress
no House purchase disclosed in the last 12 months
Funds
177 funds bought in last quarter
more than 81% of Medical Devices
Revenue
+0.7% year over year
below 77% of Medical Devices
Margin
29.4% net margin
more than 98% of Medical Devices
Buybacks
$79.3M repurchased, FY to 2026-06-30
more than 56% of Medical Devices
Short interest
5.5% of the float short (float per yahoo 2026-10-26) · 4.3 days to cover · settled 2026-09-30
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch BIO
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
Who owns BIO: institutional holders (13F)
13F holdings, latest reported quarter
5,212,438 sh
$1.5B
1,698,929 sh
$498.8M
944,548 sh
$277.3M
826,972 sh
$242.8M
816,751 sh
$239.8M
Congress trades in BIO
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
BIO planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
BIO mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Ariel Fund
$102.5M position · as of 2026-06-30
3.5%
Ariel Appreciation Fund
$22.4M position · as of 2026-06-30
2.3%
Ariel Focus Fund
$1.6M position · as of 2026-06-30
1.8%
Mid Cap Intrinsic Value Portfolio
$1.8M position · as of 2026-06-30
1.6%
Franklin Mutual U.S. Mid Cap Value Fund
$12.0M position · as of 2026-07-31
1.5%
Buffalo Mid Cap Growth Fund
$1.7M position · as of 2026-06-30
1.5%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Executive pay vs shareholder return · Norman Schwartz
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$8.0M
$7.3M
$3.0M
-48%
+5%
2024
$8.3M
$8.6M
$3.1M
-44%
+0%
2023
$7.5M
$1.0M
$2.5M
-45%
+4%
2022
$7.5M
-$5.6M
$2.6M
-28%
+7%
2021
$8.7M
$20.4M
$3.2M
+30%
+39%
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows a net $135.6K sold by insiders over 180 days, 177 funds added last quarter. Each figure is a federal filing, dated the day it went public.
BIO financials
Revenue growth
+0.7%
XBRL, annual
Net margin
29.4%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$2.6B
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM BIO
| FY Dec 2025 | $2.6B |
| FY Dec 2024 | $2.6B |
| FY Dec 2023 | $2.7B |
| FY Dec 2022 | $2.8B |
| FY Dec 2021 | $2.9B |
| Jun 2026 | $651.0M |
| Mar 2026 | $592.1M |
| Dec 2025 | $693.2M |
| Sep 2025 | $653.0M |
| Jun 2025 | $651.6M |
| Mar 2025 | $585.4M |
| Dec 2024 | $667.5M |
| Sep 2024 | $649.7M |
At each fiscal year end
Single quarter
Net margin, TTM
+8.6%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM BIO
| FY Dec 2025 | +29.4% |
| FY Dec 2024 | -71.9% |
| FY Dec 2023 | -23.9% |
| FY Dec 2022 | -129.4% |
| FY Dec 2021 | +145.6% |
| Jun 2026 | +57.1% |
| Mar 2026 | -89.0% |
| Dec 2025 | +103.9% |
| Sep 2025 | -52.4% |
| Jun 2025 | +48.8% |
| Mar 2025 | +10.9% |
| Dec 2024 | -107.2% |
| Sep 2024 | +100.5% |
At each fiscal year end
Single quarter
Free cash flow, TTM
$353.1M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM BIO
| FY Dec 2025 | $374.6M |
| FY Dec 2024 | $289.6M |
| FY Dec 2023 | $218.2M |
| FY Dec 2022 | $81.6M |
| FY Dec 2021 | $535.7M |
| Jun 2026 | $66.7M |
| Mar 2026 | $78.1M |
| Dec 2025 | $119.1M |
| Sep 2025 | $89.2M |
| Jun 2025 | $70.8M |
| Mar 2025 | $95.5M |
| Dec 2024 | $81.3M |
| Sep 2024 | $123.4M |
At each fiscal year end
Single quarter
Debt to equity
0.11x
long-term debt only, 2026-06-30; equity 2026-06-30
Debt to equity BIO
| FY Dec 2025 | 0.16x |
| FY Dec 2024 | 0.18x |
| FY Dec 2023 | 0.14x |
| FY Dec 2022 | 0.12x |
| FY Dec 2021 | 0.00x |
| Jun 2026 | 0.11x |
| Mar 2026 | 0.12x |
| Dec 2025 | 0.16x |
| Sep 2025 | 0.18x |
| Jun 2025 | 0.17x |
| Mar 2025 | 0.18x |
| Dec 2024 | 0.18x |
| Sep 2024 | 0.16x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
0.61x
TTM operating cash flow over long-term debt only, 2026-06-30
Cash flow to debt BIO
| FY Dec 2025 | 0.44x |
| FY Dec 2024 | 0.38x |
| FY Dec 2023 | 0.31x |
| FY Dec 2022 | 0.16x |
| FY Dec 2021 | 63.67x |
| Jun 2026 | 0.61x |
| Mar 2026 | 0.64x |
| Dec 2025 | 0.44x |
| Sep 2025 | 0.41x |
| Jun 2025 | 0.44x |
| Mar 2025 | 0.43x |
| Dec 2024 | 0.38x |
| Sep 2024 | 0.34x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
+3.1%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity BIO
| FY Dec 2025 | +10.8% |
| FY Dec 2024 | -24.1% |
| FY Dec 2023 | -6.9% |
| FY Dec 2022 | -31.1% |
| FY Dec 2021 | +36.1% |
| Jun 2026 | +3.1% |
| Mar 2026 | +2.5% |
| Dec 2025 | +10.8% |
| Sep 2025 | -9.5% |
| Jun 2025 | +4.6% |
| Mar 2025 | -27.5% |
| Dec 2024 | -24.1% |
| Sep 2024 | -9.8% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
+2.2%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets BIO
| FY Dec 2025 | +7.6% |
| FY Dec 2024 | -17.0% |
| FY Dec 2023 | -4.9% |
| FY Dec 2022 | -23.2% |
| FY Dec 2021 | +27.6% |
| Jun 2026 | +2.2% |
| Mar 2026 | +1.7% |
| Dec 2025 | +7.6% |
| Sep 2025 | -6.7% |
| Jun 2025 | +3.2% |
| Mar 2025 | -19.6% |
| Dec 2024 | -17.0% |
| Sep 2024 | -6.9% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
+0.4%
operating income after a 36.5% effective tax rate, over long-term debt only, 2026-06-30 plus average of 2025-06-30 and 2026-06-30 minus cash
Return on invested capital BIO
| FY Dec 2025 | +0.5% |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | +3.5% |
| Jun 2026 | +0.4% |
| Mar 2026 | +0.6% |
| Dec 2025 | +0.5% |
| Sep 2025 | n/a |
| Jun 2025 | +2.0% |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
+0.6%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed BIO
| FY Dec 2025 | +0.5% |
| FY Dec 2024 | +2.6% |
| FY Dec 2023 | +2.7% |
| FY Dec 2022 | +3.2% |
| FY Dec 2021 | +3.4% |
| Jun 2026 | +0.6% |
| Mar 2026 | +0.6% |
| Dec 2025 | +0.5% |
| Sep 2025 | +2.3% |
| Jun 2025 | +2.4% |
| Mar 2025 | +2.3% |
| Dec 2024 | +2.6% |
| Sep 2024 | +2.9% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
no close on file at or before the as-of date
P/E, trailing BIO
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
n/a
no close on file at or before the as-of date
Enterprise value BIO
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
n/a
no close on file at or before the as-of date
FCF yield BIO
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
no close on file at or before the as-of date
PEG, trailing BIO
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $2.6B | $2.6B | $2.7B | $2.8B |
| Gross profit | $1.3B | $1.4B | $1.4B | $1.6B |
| Operating income | $47.2M | $269.0M | $337.8M | $482.6M |
| Net income | $759.9M | -$1.8B | -$637.3M | -$3.6B |
| EPS (diluted) | 27.85 | -65.36 | -21.82 | -121.79 |
| Operating cash flow | $532.2M | $455.2M | $374.9M | $194.4M |
| Cash | $529.8M | $488.1M | $403.8M | $434.2M |
| Long-term debt | $1.2B | $1.2B | $1.2B | $1.2B |
| Buybacks | $295.5M | $203.6M | $428.7M | $215.7M |
SEC XBRL, fiscal years, as known on 2026-10-27
BIO Stock Sonar score 6/7 axes
Find similar shapesCompareBIO ranks highest on financial health (77th percentile) and institutional and government (72nd), and lowest on growth (23rd), among Medical Devices peers.
6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
BIO filings, in plain words
Are Bio-rad Laboratories insiders buying or selling BIO?
In the 180 days to 2026-10-27, Bio-rad Laboratories insiders were net sellers, a net $135.6K across purchases and sales reported on Form 4, by 1 seller.
Read the full summary
In the 180 days to 2026-10-27, Bio-rad Laboratories insiders were net sellers of BIO, a net $135.6K across purchases and sales reported on Form 4 by 1 seller. Each figure is counted from SEC and House filings as of 2026-10-27, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
